174 related articles for article (PubMed ID: 14674889)
1. Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: implications for dendritic cell-based immunotherapy.
Thumann P; Lüftl M; Moc I; Bagot M; Bensussan A; Schuler G; Jenne L
Br J Dermatol; 2003 Dec; 149(6):1128-42. PubMed ID: 14674889
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
3. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells.
Berger CL; Hanlon D; Kanada D; Dhodapkar M; Lombillo V; Wang N; Christensen I; Howe G; Crouch J; El-Fishawy P; Edelson R
Blood; 2002 Apr; 99(8):2929-39. PubMed ID: 11929784
[TBL] [Abstract][Full Text] [Related]
4. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma.
Schlapbach C; Ochsenbein A; Kaelin U; Hassan AS; Hunger RE; Yawalkar N
J Am Acad Dermatol; 2010 Jun; 62(6):995-1004. PubMed ID: 20466174
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells.
Berger CL; Tigelaar R; Cohen J; Mariwalla K; Trinh J; Wang N; Edelson RL
Blood; 2005 Feb; 105(4):1640-7. PubMed ID: 15514008
[TBL] [Abstract][Full Text] [Related]
6. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.
Querfeld C; Leung S; Myskowski PL; Curran SA; Goldman DA; Heller G; Wu X; Kil SH; Sharma S; Finn KJ; Horwitz S; Moskowitz A; Mehrara B; Rosen ST; Halpern AC; Young JW
Cancer Immunol Res; 2018 Aug; 6(8):900-909. PubMed ID: 29895574
[TBL] [Abstract][Full Text] [Related]
7. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells and cutaneous T-cell lymphomas.
Ni X; Duvic M
G Ital Dermatol Venereol; 2011 Apr; 146(2):103-13. PubMed ID: 21505396
[TBL] [Abstract][Full Text] [Related]
9. The life cycle of cutaneous T cell lymphoma reveals opportunities for targeted drug therapy.
Berger CL; Edelson R
Curr Cancer Drug Targets; 2004 Nov; 4(7):609-19. PubMed ID: 15578918
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells pulsed with generated tumor cell lysate from Phyllanthus amarus Schum. & Thonn. induces anti-tumor immune response.
Mohamed SIA; Jantan I; Nafiah MA; Seyed MA; Chan KM
BMC Complement Altern Med; 2018 Aug; 18(1):232. PubMed ID: 30081891
[TBL] [Abstract][Full Text] [Related]
12. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.
von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J
J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240
[TBL] [Abstract][Full Text] [Related]
13. Efficient tumor antigen loading of dendritic antigen presenting cells by transimmunization.
Girardi M; Berger C; Hanlon D; Edelson RL
Technol Cancer Res Treat; 2002 Feb; 1(1):65-9. PubMed ID: 12614179
[TBL] [Abstract][Full Text] [Related]
14. Rapid construction of a dendritic cell vaccine through physical perturbation and apoptotic malignant T cell loading.
Salskov-Iversen M; Berger CL; Edelson RL
J Immune Based Ther Vaccines; 2005 Jul; 3():4. PubMed ID: 16029505
[TBL] [Abstract][Full Text] [Related]
15. Transimmunization for cutaneous T cell lymphoma: a Phase I study.
Girardi M; Berger CL; Wilson LD; Christensen IR; Thompson KR; Glusac EJ; Edelson RL
Leuk Lymphoma; 2006 Aug; 47(8):1495-503. PubMed ID: 16966259
[TBL] [Abstract][Full Text] [Related]
16. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells.
Sauter B; Albert ML; Francisco L; Larsson M; Somersan S; Bhardwaj N
J Exp Med; 2000 Feb; 191(3):423-34. PubMed ID: 10662788
[TBL] [Abstract][Full Text] [Related]
17. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
18. Improved generation of anti-tumor immunity by antigen dose limitation.
Shofner JD; Vasquez JG; Berger CL; Edelson RL
J Immune Based Ther Vaccines; 2007 Feb; 5():2. PubMed ID: 17291350
[TBL] [Abstract][Full Text] [Related]
19. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo.
Kleindienst P; Brocker T
J Immunol; 2003 Mar; 170(6):2817-23. PubMed ID: 12626531
[TBL] [Abstract][Full Text] [Related]
20. Combined immunotherapy with whole tumor lysate-pulsed interleukin-15-activated dendritic cells and cucurbitacin I promotes strong CD8(+) T-cell responses and cures highly aggressive lymphoma.
Hira SK; Mondal I; Manna PP
Cytotherapy; 2015 May; 17(5):647-64. PubMed ID: 25769790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
